bioRxiv Science⌕ Search

Biology subjects

Swindle-Reilly, K. E.

Publications and source records attributed to Swindle-Reilly, K. E..

2 recordsLinked to original sources

Mathematical Modeling of Drug Delivery from Bi-Layered Core-Shell Polymeric Microspheres

Chronic retinal diseases usually require repetitive local dosing. Depending on factors such as dosing frequency, mode of administration, and associated costs, this can result in poor patient compliance. A better alternative involves using controlled release drug delivery systems to reduce the frequency of intravitreal dosing and extend drug release. However, reaching the market stage is a time-consuming process. In this study, we employed two computational approaches to model and estimate the parameters governing the diffusion-controlled drug release of bovine serum albumin and bevacizumab (an agent that slows neovascularization due to retinal disorders) from bi-layered core-shell microspheres composed of chitosan and polycaprolactone (PCL). We used the estimated parameters to simulate the cumulative release under various conditions, optimize device design to guide future experimental efforts and improve the duration of release above a target daily therapeutic release rate from the microspheres. We investigated the effects of polymeric layer sizes on drug release. We provided straightforward computational tools for others to reuse in designing bi-layered microspheres suitable for addressing intravitreal drug delivery needs in the treatment of ocular neovascularization in chronic retinal diseases.

pharmacology and toxicology↗

Computer Modeling of Bevacizumab Drug Distribution after Intravitreal Injection in Rabbit and Human Eyes

Age-related macular degeneration (AMD) is a progressive eye disease that causes loss of central vision and has no cure. Wet AMD is the late neovascular form treated with vascular endothelial growth factor (VEGF) inhibitors. VEGF is the critical driver of wet AMD. One common off-label anti-VEGF drug used in AMD treatment is bevacizumab. Experimental efforts have been made to investigate the pharmacokinetic (PK) behavior of bevacizumab in vitreous and aqueous humor. Still, the quantitative effect of elimination routes and drug concentration in the macula are not well understood. In this work, we developed two spatial models representing rabbit and human vitreous to better understand the PK behavior of bevacizumab. This study explores different cases of drug elimination and the effects of injection location on drug concentration profiles. The models are validated by comparing them with experimental data. Our results suggest that anterior elimination is dominant for bevacizumab clearance from rabbit vitreous, whereas both anterior and posterior elimination have similar importance in drug clearance from the human vitreous. Furthermore, results indicate that drug injections closer to the posterior segment of the vitreous help maintain relevant drug concentrations for longer, improving bevacizumab duration of action in the vitreous. The rabbit and human models predict bevacizumab concentration in the vitreous and fovea, enhancing knowledge and understanding of wet AMD treatment.

systems biology↗